TY - JOUR
T1 - Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody
AU - Gauduin, Marie Claire
AU - Safrit, Jeffrey T.
AU - Weir, Raymond
AU - Fung, Michael S.C.
AU - Koup, Richard A.
N1 - Funding Information:
Received 21 October 1994; revised 20 December 1994. Presented in part: Conference on Advances in AIDS Vaccine Development. Alexandria. Virginia. 30 October-4 November 1993 (poster 27). Protocols involving the use ofSCID mice were reviewed and approved by the Center's Institutional Animal Care and Use Committee. All animals were maintained under American Association for the Accreditation ofLaboratory Animal Care guidelines. Financial support: National Institutes of Health (AI-30358. -32427. -35522. and -45218). New York University Center for AIDS Research (AI-27742). and Pediatric AIDS Foundation (555001-I-ARI). M.-C.O. was supported by summer internship awards from the Pediatric AIDS Foundation. J.T.S. is supported by a Postdoctoral Research Fellowship from the Aaron Diamond Foundation. Reprints and correspondence: Dr. Richard A. Koup, Aaron Diamond AIDS Research Center. 455 First Ave.. 7th floor. New York. NY 10016.
PY - 1995/5
Y1 - 1995/5
N2 - Monoclonal antibody BATI23 was passively transferred into SCID mice reconstituted with human peripheral blood lymphocytes (hu-PBL-SCID) to study passive antibody protection against human immunodeficiency virus type 1 (HIV㌡) infection. BATI23 is specific for the third variable loop of the gp120 of HIV㌡LAIAnimals were protected against subsequent infection with LAI strain, but not other virus strains, when BATI23 was given 1 h before virus inoculation. This resulted in a peak serum concentration of 16 �g/mL of the antibody, which should be easily attainable in humans. In addition, postexposure protection was observed when the antibody was given within 4 h of virus inoculation. No therapeutic effect was observed, however, when BATI23 was administered after infection had been established. These results indicate that passive antibody prophylaxis against HIV-1 infection may be possible in certain clinical situations.
AB - Monoclonal antibody BATI23 was passively transferred into SCID mice reconstituted with human peripheral blood lymphocytes (hu-PBL-SCID) to study passive antibody protection against human immunodeficiency virus type 1 (HIV㌡) infection. BATI23 is specific for the third variable loop of the gp120 of HIV㌡LAIAnimals were protected against subsequent infection with LAI strain, but not other virus strains, when BATI23 was given 1 h before virus inoculation. This resulted in a peak serum concentration of 16 �g/mL of the antibody, which should be easily attainable in humans. In addition, postexposure protection was observed when the antibody was given within 4 h of virus inoculation. No therapeutic effect was observed, however, when BATI23 was administered after infection had been established. These results indicate that passive antibody prophylaxis against HIV-1 infection may be possible in certain clinical situations.
UR - http://www.scopus.com/inward/record.url?scp=0028950509&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028950509&partnerID=8YFLogxK
U2 - 10.1093/infdis/171.5.1203
DO - 10.1093/infdis/171.5.1203
M3 - Article
C2 - 7751695
AN - SCOPUS:0028950509
VL - 171
SP - 1203
EP - 1209
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 5
ER -